Skip to main content
Top
Published in: Journal of Gastroenterology 8/2012

01-08-2012 | Review

An update of the role of nutritional therapy in the management of Crohn’s disease

Authors: Moftah H. Alhagamhmad, Andrew S. Day, Daniel A. Lemberg, Steven T. Leach

Published in: Journal of Gastroenterology | Issue 8/2012

Login to get access

Abstract

Crohn’s disease is an increasingly global health concern. Currently without a cure, it significantly alters the quality of life of Crohn’s disease sufferers and places a heavy financial burden on the community. Recent reports show that the rising prevalence of Crohn’s disease is no longer confined to Western countries, with considerable increases seen particularly in Asia. Nutritional problems are often associated with Crohn’s disease, most notably in the paediatric population, with underweight and stunting commonly seen at presentation. In addition, linear growth retardation and pubertal delay can also manifest in these younger patients. Therefore, exclusive enteral nutrition has been used as a therapeutic option to treat Crohn’s disease, in part to address the nutritional complications of the disease. Exclusive enteral nutrition can improve nutrition as well as induce remission at a rate equivalent to corticosteroids. It is safe particularly with long-term use and can induce mucosal healing, considered the gold standard for therapy, at a rate superior to corticosteroids. Exclusive enteral nutrition has thus become the preferred therapeutic option in many centres for the treatment of paediatric Crohn’s disease. This review discusses the role of exclusive enteral nutrition as a therapeutic option for the treatment of Crohn’s disease, as well as the latest findings into its mechanisms of action.
Literature
1.
go back to reference Pariente B, Peyrin-Biroulet L, Cohen L, Zagdanski AM, Colombel JF. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentgenol. 2011;197:42–9.CrossRef Pariente B, Peyrin-Biroulet L, Cohen L, Zagdanski AM, Colombel JF. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentgenol. 2011;197:42–9.CrossRef
2.
go back to reference Parray F, Wani M, Bijli A, Thakur N, Irshad I. Crohn’s disease: a surgeon’s perspective. Saudi J Gastroenterol. 2011;17:6.PubMedCrossRef Parray F, Wani M, Bijli A, Thakur N, Irshad I. Crohn’s disease: a surgeon’s perspective. Saudi J Gastroenterol. 2011;17:6.PubMedCrossRef
3.
go back to reference Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef
4.
go back to reference Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.PubMedCrossRef Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.PubMedCrossRef
5.
go back to reference Wilson J, Hair C, Knight R, Catto Smith A, Bell S, Kamm M, et al. High incidence of inflammatory bowel disease in Australia: a prospective population based Australian incidence study. Inflamm Bowel Dis. 2010;16:1550–6.PubMedCrossRef Wilson J, Hair C, Knight R, Catto Smith A, Bell S, Kamm M, et al. High incidence of inflammatory bowel disease in Australia: a prospective population based Australian incidence study. Inflamm Bowel Dis. 2010;16:1550–6.PubMedCrossRef
6.
go back to reference Gearry RB, Richardson A, Frampton C, Collett JA, Burt MJ, Chapman BA, et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936–43.PubMedCrossRef Gearry RB, Richardson A, Frampton C, Collett JA, Burt MJ, Chapman BA, et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936–43.PubMedCrossRef
7.
go back to reference Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102.PubMed Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102.PubMed
8.
go back to reference Goh K, XIAO SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis. 2009;10:1–6.PubMedCrossRef Goh K, XIAO SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis. 2009;10:1–6.PubMedCrossRef
9.
go back to reference Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–65.PubMedCrossRef Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–65.PubMedCrossRef
10.
go back to reference Sartor B. Bacteria in Crohn’s disease: mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol. 2007;41:S37.CrossRef Sartor B. Bacteria in Crohn’s disease: mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol. 2007;41:S37.CrossRef
11.
go back to reference Lichtenstein GR. Emerging prognostic markers to determine Crohn’s disease natural history and improve management strategies: a review of recent literature. Gastroenterol Hepatol (N Y). 2010;6:99. Lichtenstein GR. Emerging prognostic markers to determine Crohn’s disease natural history and improve management strategies: a review of recent literature. Gastroenterol Hepatol (N Y). 2010;6:99.
13.
go back to reference Scribano M, Prantera C. Medical treatment of active Crohn’s disease. Aliment Pharmacol Ther. 2002;16:35–9.PubMedCrossRef Scribano M, Prantera C. Medical treatment of active Crohn’s disease. Aliment Pharmacol Ther. 2002;16:35–9.PubMedCrossRef
14.
go back to reference Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–63.PubMedCrossRef Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–63.PubMedCrossRef
15.
go back to reference Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.PubMedCrossRef Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.PubMedCrossRef
16.
go back to reference Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940.PubMedCrossRef Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940.PubMedCrossRef
17.
18.
go back to reference Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101.PubMedCrossRef Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101.PubMedCrossRef
19.
go back to reference Danese S, Colombel JF, Reinisch W, Rutgeerts P. Review article: infliximab for Crohn’s disease treatment—shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011. Danese S, Colombel JF, Reinisch W, Rutgeerts P. Review article: infliximab for Crohn’s disease treatment—shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011.
20.
go back to reference Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.PubMedCrossRef Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.PubMedCrossRef
21.
go back to reference Arnott IDR, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639–46.PubMedCrossRef Arnott IDR, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639–46.PubMedCrossRef
22.
go back to reference Ten Hove T, Van Montfrans C, Peppelenbosch M, Van Deventer S. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206.PubMedCrossRef Ten Hove T, Van Montfrans C, Peppelenbosch M, Van Deventer S. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206.PubMedCrossRef
23.
go back to reference Rutgeerts P, Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther. 2006;23:451–63.PubMedCrossRef Rutgeerts P, Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther. 2006;23:451–63.PubMedCrossRef
24.
go back to reference Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011. Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011.
25.
go back to reference Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.PubMedCrossRef Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.PubMedCrossRef
26.
go back to reference De Bie CI, Hummel T, Kindermann A, Kokke F, Damen GM, Kneepkens C, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther. 2011. De Bie CI, Hummel T, Kindermann A, Kokke F, Damen GM, Kneepkens C, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther. 2011.
27.
go back to reference Rubio A, Pigneur B, Garnier‐Lengliné H, Talbotec C, Schmitz J, Canioni D, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011. Rubio A, Pigneur B, Garnier‐Lengliné H, Talbotec C, Schmitz J, Canioni D, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011.
28.
go back to reference Hiwatashi N. Enteral nutrition for Crohn’s disease in Japan. Dis Colon Rectum. 1997;40:48–53.CrossRef Hiwatashi N. Enteral nutrition for Crohn’s disease in Japan. Dis Colon Rectum. 1997;40:48–53.CrossRef
29.
go back to reference El-Matary W. Enteral nutrition as a primary therapy of Crohn’s disease: the pediatric perspective. Nutr Clin Pract. 2009;24:91.PubMedCrossRef El-Matary W. Enteral nutrition as a primary therapy of Crohn’s disease: the pediatric perspective. Nutr Clin Pract. 2009;24:91.PubMedCrossRef
30.
go back to reference Day A, Whitten K, Sidler M, Lemberg D. Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2008;27:293–307.PubMedCrossRef Day A, Whitten K, Sidler M, Lemberg D. Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2008;27:293–307.PubMedCrossRef
31.
go back to reference Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treatment of inflammatory bowel disease: is this primary therapy? Arch Surg. 1973;107:329.PubMedCrossRef Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treatment of inflammatory bowel disease: is this primary therapy? Arch Surg. 1973;107:329.PubMedCrossRef
32.
go back to reference Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric crohn’s disease: A double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012. Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric crohn’s disease: A double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012.
33.
go back to reference Rajendran N, Kumar D. Role of diet in the management of inflammatory bowel disease. World J Gastroenterol. 2010;16:1442.PubMedCrossRef Rajendran N, Kumar D. Role of diet in the management of inflammatory bowel disease. World J Gastroenterol. 2010;16:1442.PubMedCrossRef
34.
go back to reference Verma S, Brown S, Kirkwood B, Giaffer M. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol. 2000;95:735–9.PubMedCrossRef Verma S, Brown S, Kirkwood B, Giaffer M. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol. 2000;95:735–9.PubMedCrossRef
35.
go back to reference Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. J Parenter Enteral Nutr. 2002;26:98–103.CrossRef Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. J Parenter Enteral Nutr. 2002;26:98–103.CrossRef
36.
go back to reference Heuschkel R. Enteral nutrition in crohn disease: more than just calories. J Pediatr Gastroenterol Nutr. 2004;38:239.PubMedCrossRef Heuschkel R. Enteral nutrition in crohn disease: more than just calories. J Pediatr Gastroenterol Nutr. 2004;38:239.PubMedCrossRef
37.
go back to reference Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009;15:2570.PubMedCrossRef Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009;15:2570.PubMedCrossRef
38.
go back to reference Zachos M, Tondeur M, Griffiths A. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;24:CD000542. Zachos M, Tondeur M, Griffiths A. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;24:CD000542.
39.
go back to reference Beattie RM. Enteral nutrition as primary therapy in childhood Crohn’s disease: control of intestinal inflammation and anabolic response. J Parenter Enteral Nutr. 2005;29:S151–9.CrossRef Beattie RM. Enteral nutrition as primary therapy in childhood Crohn’s disease: control of intestinal inflammation and anabolic response. J Parenter Enteral Nutr. 2005;29:S151–9.CrossRef
40.
go back to reference Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn’s disease: fact or fantasy? J Pediatr. 2000;136:285.PubMedCrossRef Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn’s disease: fact or fantasy? J Pediatr. 2000;136:285.PubMedCrossRef
41.
go back to reference Escher JC, Taminiau JAJM, Nieuwenhuis EES, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34–58.PubMedCrossRef Escher JC, Taminiau JAJM, Nieuwenhuis EES, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34–58.PubMedCrossRef
42.
go back to reference Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn’s disease. Dig Dis. 2009;27:297–305.PubMedCrossRef Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn’s disease. Dig Dis. 2009;27:297–305.PubMedCrossRef
43.
go back to reference Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr. 2003;36:464.PubMedCrossRef Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr. 2003;36:464.PubMedCrossRef
44.
go back to reference Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clini Nutr. 2006;25:260–74.CrossRef Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clini Nutr. 2006;25:260–74.CrossRef
45.
go back to reference Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn’s disease in Japan. J Gastroenterol. 2005;40:25–31.PubMedCrossRef Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn’s disease in Japan. J Gastroenterol. 2005;40:25–31.PubMedCrossRef
46.
go back to reference Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609–14.PubMedCrossRef Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609–14.PubMedCrossRef
47.
go back to reference Berni B, Canani R, Terrin G, Borrelli O, Romano M, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig liver Dis. 2006;38:381–7.CrossRef Berni B, Canani R, Terrin G, Borrelli O, Romano M, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig liver Dis. 2006;38:381–7.CrossRef
48.
go back to reference Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8.PubMedCrossRef Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8.PubMedCrossRef
49.
go back to reference Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther. 2007;26:795–806.PubMedCrossRef Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther. 2007;26:795–806.PubMedCrossRef
50.
go back to reference Buchanan E, Gaunt W, Cardigan T, Garrick V, McGrogan P, Russell R. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–7.PubMedCrossRef Buchanan E, Gaunt W, Cardigan T, Garrick V, McGrogan P, Russell R. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–7.PubMedCrossRef
51.
go back to reference Sanderson I, Udeen S, Davies P, Savage M, Walker-Smith J. Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child. 1987;62:123–7.PubMedCrossRef Sanderson I, Udeen S, Davies P, Savage M, Walker-Smith J. Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child. 1987;62:123–7.PubMedCrossRef
52.
go back to reference Seidman E, Lohoues M, Turgeon J, Bouthillier L, Morin C. Elemental diet versus prednisone as initial therapy in Crohn’s disease: early and long term results. Gastroenterology. 1991;100:A250. Seidman E, Lohoues M, Turgeon J, Bouthillier L, Morin C. Elemental diet versus prednisone as initial therapy in Crohn’s disease: early and long term results. Gastroenterology. 1991;100:A250.
53.
go back to reference Seidman E, Griffiths A, Jones A, Issenman R. Semi-elemental (SE) diet versus prednisone in pediatric Crohn’s disease. Gastroenterology. 1993;104:A778. Seidman E, Griffiths A, Jones A, Issenman R. Semi-elemental (SE) diet versus prednisone in pediatric Crohn’s disease. Gastroenterology. 1993;104:A778.
54.
go back to reference Thomas A, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr. 1993;17:75.PubMedCrossRef Thomas A, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr. 1993;17:75.PubMedCrossRef
55.
go back to reference Ruuska T, Savilahti E, Mäki M, Örmälä T, Visakorpi J. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 1994;19:175.PubMedCrossRef Ruuska T, Savilahti E, Mäki M, Örmälä T, Visakorpi J. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 1994;19:175.PubMedCrossRef
56.
go back to reference Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn’s disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis. 2005;11:580–8.PubMedCrossRef Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn’s disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis. 2005;11:580–8.PubMedCrossRef
57.
go back to reference Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.PubMedCrossRef Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.PubMedCrossRef
58.
go back to reference Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin Nutr. 2005;24:775–9.PubMedCrossRef Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin Nutr. 2005;24:775–9.PubMedCrossRef
59.
go back to reference Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333–40.PubMedCrossRef Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333–40.PubMedCrossRef
60.
go back to reference Esaki M, Matsumoto T, Nakamura S, Yada S, Fujisawa K, Jo Y, et al. Factors affecting recurrence in patients with Crohn’s disease under nutritional therapy. Dis Colon Rectum. 2006;49:68–74.CrossRef Esaki M, Matsumoto T, Nakamura S, Yada S, Fujisawa K, Jo Y, et al. Factors affecting recurrence in patients with Crohn’s disease under nutritional therapy. Dis Colon Rectum. 2006;49:68–74.CrossRef
61.
go back to reference Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review. Eur J Gastroenterol Hepatol. 2010;22:1.PubMedCrossRef Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review. Eur J Gastroenterol Hepatol. 2010;22:1.PubMedCrossRef
62.
go back to reference Ikeuchi H, Yamamura T, Nakano H, Kosaka T, Shimoyama T, Fukuda Y. Efficacy of nutritional therapy for perforating and non-perforating Crohn’s disease. Hepatogastroenterology. 2004;51:1050–2.PubMed Ikeuchi H, Yamamura T, Nakano H, Kosaka T, Shimoyama T, Fukuda Y. Efficacy of nutritional therapy for perforating and non-perforating Crohn’s disease. Hepatogastroenterology. 2004;51:1050–2.PubMed
63.
go back to reference Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol. 2005;40:1431–7.PubMedCrossRef Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol. 2005;40:1431–7.PubMedCrossRef
64.
go back to reference Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493–501.PubMedCrossRef Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493–501.PubMedCrossRef
65.
go back to reference Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25:67–72.PubMedCrossRef Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25:67–72.PubMedCrossRef
66.
go back to reference Lucendo AJ, De Rezende LC. Importance of nutrition in inflammatory bowel disease. World J Gastroenterol. 2009;15:2081.PubMedCrossRef Lucendo AJ, De Rezende LC. Importance of nutrition in inflammatory bowel disease. World J Gastroenterol. 2009;15:2081.PubMedCrossRef
67.
go back to reference Goulet O. Nutrition in paediatric Crohn’s disease. S Afr J Clin Nutr. 2010;23. Goulet O. Nutrition in paediatric Crohn’s disease. S Afr J Clin Nutr. 2010;23.
68.
go back to reference Beattie R, Schiffrin E, Donnet-Hughes A, Huggett A, Domizio P, MacDonald T, et al. Polgmeric nutrition as the primary therapy in children with small bowel Crohn’s disease. Aliment Pharmacol Ther. 1994;8:609–15.PubMedCrossRef Beattie R, Schiffrin E, Donnet-Hughes A, Huggett A, Domizio P, MacDonald T, et al. Polgmeric nutrition as the primary therapy in children with small bowel Crohn’s disease. Aliment Pharmacol Ther. 1994;8:609–15.PubMedCrossRef
69.
go back to reference Breese E, Michie C, Nicholls S, Williams C. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment Pharmacol Ther. 1995;9:547–52.PubMedCrossRef Breese E, Michie C, Nicholls S, Williams C. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment Pharmacol Ther. 1995;9:547–52.PubMedCrossRef
70.
go back to reference Fell J, Paintin M, Arnaud-Battandier F, Beattie R, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2000;14:281–90.PubMedCrossRef Fell J, Paintin M, Arnaud-Battandier F, Beattie R, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2000;14:281–90.PubMedCrossRef
71.
go back to reference Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38:270.PubMedCrossRef Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38:270.PubMedCrossRef
72.
go back to reference Meister D, Bode J, Shand A, Ghosh S. Anti-inflammatory effects of enteral diet components on Crohn’s disease-affected tissues in vitro. Dig Liver Dis. 2002;34:430–8.PubMedCrossRef Meister D, Bode J, Shand A, Ghosh S. Anti-inflammatory effects of enteral diet components on Crohn’s disease-affected tissues in vitro. Dig Liver Dis. 2002;34:430–8.PubMedCrossRef
73.
go back to reference de Jong NSH, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig Dis Sci. 2007;52:2029–36.PubMedCrossRef de Jong NSH, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig Dis Sci. 2007;52:2029–36.PubMedCrossRef
74.
go back to reference Flaring U, Rooyackers O, Wernerman J, Hammarqvist F. Glutamine attenuates post-traumatic glutathione depletion in human muscle. Clin Sci. 2003;104:275–82.PubMedCrossRef Flaring U, Rooyackers O, Wernerman J, Hammarqvist F. Glutamine attenuates post-traumatic glutathione depletion in human muscle. Clin Sci. 2003;104:275–82.PubMedCrossRef
75.
go back to reference Morrison AL, Dinges M, Singleton KD, Odoms K, Wong HR, Wischmeyer PE. Glutamine’s protection against cellular injury is dependent on heat shock factor-1. Am J Physiol Cell Physiol. 2006;290:C1625.PubMedCrossRef Morrison AL, Dinges M, Singleton KD, Odoms K, Wong HR, Wischmeyer PE. Glutamine’s protection against cellular injury is dependent on heat shock factor-1. Am J Physiol Cell Physiol. 2006;290:C1625.PubMedCrossRef
76.
go back to reference Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, et al. Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med. 2003;31:2444.PubMedCrossRef Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, et al. Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med. 2003;31:2444.PubMedCrossRef
77.
go back to reference Boelens PG, Houdijk APJ, Fonk J, Nijveldt RJ, Ferwerda CC, Von Blomberg-Van der Flier BME, et al. Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J Nutr. 2002;132:2580–6.PubMed Boelens PG, Houdijk APJ, Fonk J, Nijveldt RJ, Ferwerda CC, Von Blomberg-Van der Flier BME, et al. Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J Nutr. 2002;132:2580–6.PubMed
78.
go back to reference Wischmeyer PE, Lynch J, Liedel J, Wolfson R, Riehm J, Gottlieb L, et al. Glutamine administration reduces Gram-negative bacteremia in severely burned patients: a prospective, randomized, double-blind trial versus isonitrogenous control. Crit Care Med. 2001;29:2075.PubMedCrossRef Wischmeyer PE, Lynch J, Liedel J, Wolfson R, Riehm J, Gottlieb L, et al. Glutamine administration reduces Gram-negative bacteremia in severely burned patients: a prospective, randomized, double-blind trial versus isonitrogenous control. Crit Care Med. 2001;29:2075.PubMedCrossRef
79.
go back to reference Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P, et al. Parenteral l-alanyl-l-glutamine improves 6-month outcome in critically ill patients. Crit Care Med. 2002;30:2032.PubMedCrossRef Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P, et al. Parenteral l-alanyl-l-glutamine improves 6-month outcome in critically ill patients. Crit Care Med. 2002;30:2032.PubMedCrossRef
80.
go back to reference Singleton KD, Wischmeyer PE. Glutamine’s protection against sepsis and lung injury is dependent on heat shock protein 70 expression. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1839.PubMedCrossRef Singleton KD, Wischmeyer PE. Glutamine’s protection against sepsis and lung injury is dependent on heat shock protein 70 expression. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1839.PubMedCrossRef
81.
go back to reference Fillmann H, Kretzmann NA, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007;236:217–26.PubMedCrossRef Fillmann H, Kretzmann NA, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007;236:217–26.PubMedCrossRef
82.
go back to reference Li N, Liboni K, Fang MZ, Samuelson D, Lewis P, Patel R, et al. Glutamine decreases lipopolysaccharide-induced intestinal inflammation in infant rats. Am J Physiol Gastrointest Liver Physiol. 2004;286:G914–21.PubMedCrossRef Li N, Liboni K, Fang MZ, Samuelson D, Lewis P, Patel R, et al. Glutamine decreases lipopolysaccharide-induced intestinal inflammation in infant rats. Am J Physiol Gastrointest Liver Physiol. 2004;286:G914–21.PubMedCrossRef
83.
go back to reference Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bôle-Feysot C, et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr. 2008;138:2481.PubMedCrossRef Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bôle-Feysot C, et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr. 2008;138:2481.PubMedCrossRef
84.
go back to reference Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003;15:151.PubMedCrossRef Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003;15:151.PubMedCrossRef
85.
go back to reference Gassull M, Fernandez-Banares F, Cabre E, Papo M, Giaffer M, Sanchez-Lombrana J, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut. 2002;51:164–8.PubMedCrossRef Gassull M, Fernandez-Banares F, Cabre E, Papo M, Giaffer M, Sanchez-Lombrana J, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut. 2002;51:164–8.PubMedCrossRef
86.
go back to reference Gorard DA. Enteral nutrition in Crohn’s disease: fat in the formula. Eur J Gastroenterol Hepatol. 2003;15:115.PubMedCrossRef Gorard DA. Enteral nutrition in Crohn’s disease: fat in the formula. Eur J Gastroenterol Hepatol. 2003;15:115.PubMedCrossRef
87.
go back to reference Mañé J, Pedrosa E, Lorén V, Ojanguren I, Fluvià L, Cabré E, et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. J Nutr. 2009;139:603–10.PubMedCrossRef Mañé J, Pedrosa E, Lorén V, Ojanguren I, Fluvià L, Cabré E, et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. J Nutr. 2009;139:603–10.PubMedCrossRef
88.
go back to reference Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741–5.PubMed Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741–5.PubMed
89.
go back to reference Hartman C, Berkowitz D, Weiss B, Shaoul R, Levine A, Adiv OE, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease. Isr Med Assoc J. 2008;10:503–7.PubMed Hartman C, Berkowitz D, Weiss B, Shaoul R, Levine A, Adiv OE, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease. Isr Med Assoc J. 2008;10:503–7.PubMed
90.
go back to reference D’Haens G. Mucosal healing in pediatric Crohn’s disease. The goal of medical treatment. Inflamm Bowel Dis. 2004;10:479–80.PubMedCrossRef D’Haens G. Mucosal healing in pediatric Crohn’s disease. The goal of medical treatment. Inflamm Bowel Dis. 2004;10:479–80.PubMedCrossRef
91.
go back to reference Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjaranson I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.PubMedCrossRef Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjaranson I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.PubMedCrossRef
92.
go back to reference Afzal N, Van Der Zaag-Loonen H, Arnaud-Battandier F, Davies S, Murch S, Derkx B, et al. Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167–72.PubMedCrossRef Afzal N, Van Der Zaag-Loonen H, Arnaud-Battandier F, Davies S, Murch S, Derkx B, et al. Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167–72.PubMedCrossRef
93.
go back to reference Lionetti P, Callegari ML, Ferrari S, Cavicchi MC, Pozzi E, de Martino M, et al. Enteral nutrition and microflora in pediatric Crohn’s disease. J Parenter Enteral Nutr. 2005;29:S173.CrossRef Lionetti P, Callegari ML, Ferrari S, Cavicchi MC, Pozzi E, de Martino M, et al. Enteral nutrition and microflora in pediatric Crohn’s disease. J Parenter Enteral Nutr. 2005;29:S173.CrossRef
94.
go back to reference Leach S, Mitchell H, Eng W, Zhang L, Day A. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008;28:724–33.PubMedCrossRef Leach S, Mitchell H, Eng W, Zhang L, Day A. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008;28:724–33.PubMedCrossRef
95.
go back to reference Greenberg G, Fleming C, Jeejeebhoy K, Rosenberg I, Sales D, Tremaine W. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut. 1988;29:1309.PubMedCrossRef Greenberg G, Fleming C, Jeejeebhoy K, Rosenberg I, Sales D, Tremaine W. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut. 1988;29:1309.PubMedCrossRef
96.
go back to reference Newby E, Sawczenko A, Thomas A, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005;3:CD003873. Newby E, Sawczenko A, Thomas A, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005;3:CD003873.
97.
go back to reference Sawczenko A, Sandhu B. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995–1000.PubMedCrossRef Sawczenko A, Sandhu B. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995–1000.PubMedCrossRef
98.
go back to reference Yamamoto T, Nakahigashi M, Saniabadi A. Review article: diet and inflammatory bowel disease–epidemiology and treatment. Aliment Pharmacol Ther. 2009;30:99–112.PubMedCrossRef Yamamoto T, Nakahigashi M, Saniabadi A. Review article: diet and inflammatory bowel disease–epidemiology and treatment. Aliment Pharmacol Ther. 2009;30:99–112.PubMedCrossRef
99.
go back to reference Wiskin AE, Wootton SA, Beattie RM. Nutrition issues in pediatric Crohn’s disease. Nutr Clin Pract. 2007;22:214–22.PubMedCrossRef Wiskin AE, Wootton SA, Beattie RM. Nutrition issues in pediatric Crohn’s disease. Nutr Clin Pract. 2007;22:214–22.PubMedCrossRef
100.
go back to reference Moorthy D, Cappellano KL, Rosenberg IH. Nutrition and Crohn’s disease: an update of print and web-based guidance. Nutr Rev. 2008;66:387–97.PubMedCrossRef Moorthy D, Cappellano KL, Rosenberg IH. Nutrition and Crohn’s disease: an update of print and web-based guidance. Nutr Rev. 2008;66:387–97.PubMedCrossRef
101.
go back to reference Goh J, O’Morain C. Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:307–20.PubMedCrossRef Goh J, O’Morain C. Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:307–20.PubMedCrossRef
102.
go back to reference Shamir R. Nutritional aspects in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:S86.PubMedCrossRef Shamir R. Nutritional aspects in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:S86.PubMedCrossRef
103.
go back to reference Hébuterne X, Filippi J, Al-Jaouni R, Schneider S. Nutritional consequences and nutrition therapy in Crohn’s disease. Gastroenterol Clin Biol. 2009;33:S235–44.PubMedCrossRef Hébuterne X, Filippi J, Al-Jaouni R, Schneider S. Nutritional consequences and nutrition therapy in Crohn’s disease. Gastroenterol Clin Biol. 2009;33:S235–44.PubMedCrossRef
104.
go back to reference Gerasimidis K, McGrogan P, Edwards C. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet. 2011;24:313–26.PubMedCrossRef Gerasimidis K, McGrogan P, Edwards C. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet. 2011;24:313–26.PubMedCrossRef
105.
go back to reference Savage M, Beattie R, Camacho-Hübner C, Walker-Smith J, Sanderson I. Growth in Crohn’s disease. Acta Paediatr. 1999;88:89–92.CrossRef Savage M, Beattie R, Camacho-Hübner C, Walker-Smith J, Sanderson I. Growth in Crohn’s disease. Acta Paediatr. 1999;88:89–92.CrossRef
106.
go back to reference De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643.PubMedCrossRef De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643.PubMedCrossRef
107.
go back to reference Ballinger A, Azooz O, El-Haj T, Poole S, Farthing M. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:695.CrossRef Ballinger A, Azooz O, El-Haj T, Poole S, Farthing M. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:695.CrossRef
108.
go back to reference MacRae V, Farquharson C, Ahmed S. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol. 2006;189:319.PubMedCrossRef MacRae V, Farquharson C, Ahmed S. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol. 2006;189:319.PubMedCrossRef
109.
go back to reference Wong S, Smyth A, McNeill E, Galloway P, Hassan K, McGrogan P, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf). 2010;73:220–8. Wong S, Smyth A, McNeill E, Galloway P, Hassan K, McGrogan P, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf). 2010;73:220–8.
110.
go back to reference Street ME, de’Angelis GL, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res Paediatr. 2004;61:159–64. Street ME, de’Angelis GL, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res Paediatr. 2004;61:159–64.
111.
go back to reference Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm Bowel Dis. 2007;13:620–8.PubMedCrossRef Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm Bowel Dis. 2007;13:620–8.PubMedCrossRef
112.
go back to reference Seidman E. Nutritional therapy for Crohn’s disease: lessons from the Ste.-Justine hospital experience. Inflamm Bowel Dis. 1997;3:49–53.CrossRef Seidman E. Nutritional therapy for Crohn’s disease: lessons from the Ste.-Justine hospital experience. Inflamm Bowel Dis. 1997;3:49–53.CrossRef
113.
go back to reference Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of pediatric Crohn’s disease. Expert Rev Clin Immunol. 2010;6:667–76.PubMedCrossRef Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of pediatric Crohn’s disease. Expert Rev Clin Immunol. 2010;6:667–76.PubMedCrossRef
114.
go back to reference Wiskin AE, Wootton SA, Hunt TM, Cornelius VR, Afzal NA, Jackson AA, et al. Body composition in childhood inflammatory bowel disease. Clin Nutr. 2011;30:112–5.PubMedCrossRef Wiskin AE, Wootton SA, Hunt TM, Cornelius VR, Afzal NA, Jackson AA, et al. Body composition in childhood inflammatory bowel disease. Clin Nutr. 2011;30:112–5.PubMedCrossRef
115.
go back to reference Lee KM. Nutrition in inflammatory bowel disease. Korean J Gastroenterol. 2008;52:1–8.PubMed Lee KM. Nutrition in inflammatory bowel disease. Korean J Gastroenterol. 2008;52:1–8.PubMed
116.
go back to reference Seidman E. Nutritional management of inflammatory bowel disease. Gastroenterol Clin North Am. 1989;18:129.PubMed Seidman E. Nutritional management of inflammatory bowel disease. Gastroenterol Clin North Am. 1989;18:129.PubMed
117.
go back to reference O’Morain C, Segal A, Levi A. Elemental diets in treatment of acute Crohn’s disease. Br Med J. 1980;281:1173–5.PubMedCrossRef O’Morain C, Segal A, Levi A. Elemental diets in treatment of acute Crohn’s disease. Br Med J. 1980;281:1173–5.PubMedCrossRef
118.
go back to reference Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Effect of a vegetable-protein-rich polymeric diet treatment on body composition and energy metabolism in inactive Crohn’s disease. Eur J Gastroenterol Hepatol. 2000;12:5.PubMedCrossRef Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Effect of a vegetable-protein-rich polymeric diet treatment on body composition and energy metabolism in inactive Crohn’s disease. Eur J Gastroenterol Hepatol. 2000;12:5.PubMedCrossRef
119.
go back to reference Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN. Total enteral nutrition support improves body composition of patients with active Crohn’s disease. J Parenter Enteral Nutr. 1995;19:95–9.CrossRef Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN. Total enteral nutrition support improves body composition of patients with active Crohn’s disease. J Parenter Enteral Nutr. 1995;19:95–9.CrossRef
120.
go back to reference Alastair F, Emma G, Emma P. Nutrition in inflammatory bowel disease. J Parenter Enteral Nutr. 2011;35:571–80.CrossRef Alastair F, Emma G, Emma P. Nutrition in inflammatory bowel disease. J Parenter Enteral Nutr. 2011;35:571–80.CrossRef
121.
go back to reference Whitten KE, Rogers P, Ooi CKY, Day AS. International survey of enteral nutrition protocols used in children with Crohn’s disease. J Dig Dis. 2012;13:107–12.PubMedCrossRef Whitten KE, Rogers P, Ooi CKY, Day AS. International survey of enteral nutrition protocols used in children with Crohn’s disease. J Dig Dis. 2012;13:107–12.PubMedCrossRef
122.
go back to reference Gråfors JM, Casswall TH. Exclusive enteral nutrition in the treatment of children with Crohn’s disease in Sweden: a questionnaire survey. Acta Paediatr. 2011;100:1018–22.PubMedCrossRef Gråfors JM, Casswall TH. Exclusive enteral nutrition in the treatment of children with Crohn’s disease in Sweden: a questionnaire survey. Acta Paediatr. 2011;100:1018–22.PubMedCrossRef
123.
go back to reference Stewart M, Day AS, Otley A. Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr. 2011;52:38.PubMedCrossRef Stewart M, Day AS, Otley A. Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr. 2011;52:38.PubMedCrossRef
124.
go back to reference Scholz D. The role of nutrition in the etiology of inflammatory bowel disease. Curr Probl Pediatr Adolesc Health Care. 2011;41:248–53.PubMedCrossRef Scholz D. The role of nutrition in the etiology of inflammatory bowel disease. Curr Probl Pediatr Adolesc Health Care. 2011;41:248–53.PubMedCrossRef
125.
Metadata
Title
An update of the role of nutritional therapy in the management of Crohn’s disease
Authors
Moftah H. Alhagamhmad
Andrew S. Day
Daniel A. Lemberg
Steven T. Leach
Publication date
01-08-2012
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2012
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0617-9

Other articles of this Issue 8/2012

Journal of Gastroenterology 8/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.